Is PRQR or PRTA more undervalued in 2026?

CirclFi compares ProQR Therapeutics N.V. (PRQR) and Prothena Corporation plc (PRTA) using 13 institutional-grade valuation models. PRQR has a Quality of Company score of 5.0/10 while PRTA scores 6.8/10.

Which is a better buy — PRQR or PRTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRQR and PRTA valuations compare?

PRQR at $1.57 and PRTA at $9.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRQR vs PRTA Valuation Comparison 2026 — Intrinsic Value Analysis

PRQR

Biotechnology

ProQR Therapeutics N.V.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$1.57

Last close

Models

8/13

Active

PRTA

Biotechnology

Prothena Corporation plc

Quality

6.8

out of 10

Value Trap

LOW

Price

$9.98

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	PRQR Fair Value	PRQR Upside	PRTA Fair Value	PRTA Upside
Bayesian DCF	Intrinsic	$1.07	-32.1%	$4.46	-55.3%
Earnings Power Value	Intrinsic	—	—	$6.84	-35.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.78	-50.4%	$8.92	-10.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRQR vs PRTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRQR vs PRTA — Which Stock Is More Undervalued?

PRTA scores higher with a 6.8/10 quality rating vs PRQR's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ProQR Therapeutics N.V. (PRQR) and Prothena Corporation plc (PRTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRQR currently trades at $1.57 with a QOC of 5.0/10, while PRTA trades at $9.98 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).